The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1640
December 27, 2021
View Complete Issue         Table of Contents 2019 
Clascoterone Cream (Winlevi) for Acne
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Clascoterone Cream (Winlevi) for Acne
December 27, 2021 (Issue: 1640)
The FDA has approved Winlevi (Sun), a 1% cream formulation of the androgen receptor inhibitor clascoterone, for treatment of acne vulgaris in patients ≥12 years old. It is the first topical androgen receptor inhibitor to be approved by the...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Clascoterone Cream (Winlevi) for Acne
Article code: 1640b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.